MedTrace Logo

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

NCT06435676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-05-22

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.

Conditions

  • Overweight or Obesity; Type 2 Diabetes

Interventions

DRUG

HRS9531

Single dose escalation of HRS9531 tablets in healthy subjects

DRUG

Placebo

Single dose of placebo in healthy adults

DRUG

HRS9531

Multiple dose escalation of HRS9531 tablets in healthy subjects

DRUG

Placebo

Multiple dose of placebo in healthy adults

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-04
Primary Completion
2024-10-08
Completion
2024-10-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435676 on ClinicalTrials.gov